12/4
09:08 am
kytx
Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
11/25
01:53 pm
kytx
Kyverna Therapeutics (NASDAQ:KYTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Kyverna Therapeutics (NASDAQ:KYTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
12:28 pm
kytx
Kyverna Therapeutics GAAP EPS of -$0.85 misses by $0.04 [Seeking Alpha]
Medium
Report
Kyverna Therapeutics GAAP EPS of -$0.85 misses by $0.04 [Seeking Alpha]
11/12
07:10 pm
kytx
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Medium
Report
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
11/12
04:05 pm
kytx
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Medium
Report
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
11/12
01:27 pm
kytx
Kyverna Therapeutics (NASDAQ:KYTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Kyverna Therapeutics (NASDAQ:KYTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/10
08:00 am
kytx
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
Low
Report
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
11/3
08:00 am
kytx
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
Medium
Report
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
10/29
01:05 pm
kytx
Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
10/29
06:30 am
kytx
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
Medium
Report
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
10/27
08:06 am
kytx
Kyverna Therapeutics (NASDAQ:KYTX) had its price target raised by analysts at HC Wainwright from $10.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
Kyverna Therapeutics (NASDAQ:KYTX) had its price target raised by analysts at HC Wainwright from $10.00 to $20.00. They now have a "buy" rating on the stock.
10/25
11:07 am
kytx
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 [Yahoo! Finance]
Low
Report
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 [Yahoo! Finance]
10/25
11:00 am
kytx
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
Medium
Report
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
10/22
08:00 am
kytx
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
Medium
Report
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
10/8
08:20 am
kytx
Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
High
Report
Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
10/2
07:17 am
kytx
KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation Into Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Low
Report
KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation Into Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
9/24
09:05 am
kytx
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
Low
Report
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
9/15
01:28 pm
kytx
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 [Yahoo! Finance]
Low
Report
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 [Yahoo! Finance]
9/15
01:02 pm
kytx
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025
Low
Report
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025